8:04AM Sinovac Biotech receives tenders in Beijing and Shanghai to supply inactivated Hepatitis A vaccine healive under expanded immunization program (SVA) 2.49 : Co announced that it has been selected by the Beijing Health Bureau and the Shanghai Centers for Disease Control and Prevention to supply the Company's inactivated hepatitis A vaccine, Healive, to the Expanded Program of Immunization for each city. The tenders awarded to Sinovac in Beijing and Shanghai are valued at ~20 mln RMB and 13 million RMB, respectively. The vaccine purchased by the Beijing Health Bureau will be administered over a two year period to the pediatric population across the city. The vaccine purchased by the Shanghai CDC is for the 2012 pediatric population inoculation program.
Market Data 
Markets 
AI
